Targeted alpha-particle therapy in neuroendocrine neoplasms: A systematic review.

ABSTRACT: Neuroendocrine neoplasms (NENs) are a very diverse group of tumors with a worldwide rise in incidence. Systemic therapy remains the mainstay treatment for unresectable and/or metastatic NENs. ¹⁷⁷Lu-DOTATATE, a radiopharmaceutical which emits beta particles, has emerged as a promising therapy for metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). However, limited treatment options are available particularly after the failure of ¹⁷⁷Lu-DOTATATE therapy. This review aims to identify and summarize the available evidence for, and potential adverse events of, targeted alpha-particle therapy (TAT) in the treatment of metastatic NENs, specifically GEP-NENs. The MEDLINE, EMBASE, SCOPUS, and Cochrane Library databases were searched. Two articles which met the

SUBMITTER: Koh TT 

PROVIDER: S-EPMC8686738 | biostudies-literature | 2021 Oct-Dec

REPOSITORIES: biostudies-literature